OTC vaginal contraceptive NDAs would each cost $1 mil., NDMA estimates.
This article was originally published in The Tan Sheet
OTC VAGINAL CONTRACEPTIVE NDAs WOULD COST $1 MIL. per application to develop, conduct, and analyze a clinical study that would simulate "actual conditions of use," NDMA maintained in June 5 comments to FDA. In response to the agency's call for NDAs for OTC vaginal contraceptives under a tentative final monograph published Feb. 3, the Nonprescription Drug Manufacturers Association stated that "the estimated cost for development, conduct and analysis of a clinical study to address FDA's proposal for an in vivo study to support each vaginal spermicide through an NDA range would be in the range of $1 mil."
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC